Objective France has large markets for pharmaceuticals in Algeria; moreover, Algerian authorities look to France for reference pricing.  In recent times, the HAS is increasingly the influential health technology assessment (HTA) agency.   French speaking countries are referencing and following the HAS decisions. The main objective of this study is to assess the HAS influence in North Africa region (Morocco, Algeria, Tunisia) in their reimbursement decisions. Method To have a comprehensive study, a sample of medicines was determined, and these drugs had obtained positive recommendation by HAS during a period from  January 2013 to December 2013.Then, the recommendation from HAS were matched with the North African decision. Result Total drugs approved for their first inscription were 258, where one drug obtained ASMR II,  12 obtained ASMR III, 13 noted ASMR IV and 232 ASMR V. When we have analyzed the common reimbursement decision taken according the level of ASMR We have observed that Morocco reimburse the drugs product with ASMR III and ASMR IV. However Algeria and Tunisia reimburse less the medicines with ASMR IV and V Conclusion This study demonstrates that the discordance between countries reimbursement decisions.  In most cases it may reflect the differences in the decision making process and in their constraint budget: Payers in Morocco are following HAS recommendation whereas Tunisia and Algeria there are following less HAS decisions.